menu ☰
menu ˟

Upadacitinib outperforms adalimumab in methotrexate-refractory RA

29 Jul 2019
Upadacitinib, a JAK1 inhibitor, is superior to adalimumab and placebo at improving signs, symptoms and physical function among patients with rheumatoid arthritis who have had an inadequate response to methotrexate, according to data published in Arth...

Click here to view the full article which appeared in Rheumatology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.